If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Pin to quick picksProvexis Share News (PXS)

Share Price Information for Provexis (PXS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.55
Bid: 0.55
Ask: 0.60
Change: 0.00 (0.00%)
Spread: 0.05 (9.091%)
Open: 0.60
High: 0.60
Low: 0.55
Prev. Close: 0.575
PXS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Provexis Expects To Report "Another Strong Year Of Progress"

Tue, 31st May 2016 10:51

LONDON (Alliance News) - Provexis PLC Tuesday said it expects to report "another strong year of progress" for its year to end-March, with revenue more than doubled from the previous year.

The company, which develops and licences a heart-health food ingredient called Fruitflow, said its revenue for the year was GBP92,000, more than double the GBP38,000 it reported the year before, helped by its agreement with DSM Nutritional Products, part of DSM NV.

Provexis said DSM has continued to develop the market for Fruitflow, with more than 50 regional consumer healthcare brands launched by customers of DSM. DSM has also agreed a number of further commercial projects with prospective customers.

"Interest in the technology exists in all major global markets and the total value of the prospective sales pipeline continues to increase," said Chairman Dawson Buck in a statement.

"In June 2016 the company expects to launch a high quality dietary supplement product containing Fruitflow and Omega-3 which is expected to provide the company with an additional income and profit stream, and help to increase the brand awareness of Fruitflow more widely," Buck added.

Shares in Provexis were untraded Tuesday. They last closed at 0.312 pence.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
3 Dec 2009 08:49

Small caps round-up: Landore Resources, TXO, Aortech...

Shares in Landore Resources jumped after the Canadian miner said it made a 'significant gold discovery' in its Junior Lake property in the province of Ontario. Shares in Texas-focused oil and gas firm TXO slumped after it said oil production in the six months to September 30 fell to 13,221 barrels

Read more
3 Nov 2009 12:16

Small cap round-up: Provexis, Puricore, Sirius, Sopheon, Spiritel

Food technology group Provexis says it has been told that the European Commission review into the health claim wording for its Fruitflow anti-thrombatic technology for use on consumer products is now in "an advanced stage". Puricore's third quarter sales rose 25% to $10.8m, with the nine month tot

Read more
11 Aug 2009 09:30

Provexis surges on Crohn's disease trial

Provexis, the life-science business, has begun a clinical trial for its NSP#3G plantain medical food for Crohn's disease patients. "With the trial now starting and combined with recently obtained healthy human data, the Company will now commence seeking to identify potential global license or co-de

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.